U.S. markets open in 8 hours 44 minutes

Cytokinetics, Incorporated (CYTK)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
53.54+1.72 (+3.32%)
At close: 04:00PM EDT
54.50 +0.96 (+1.79%)
After hours: 06:59PM EDT

Cytokinetics, Incorporated

350 Oyster Point Boulevard
South San Francisco, CA 94080
United States
650 624 3000

Full Time Employees253

Key Executives

NameTitlePayExercisedYear Born
Mr. Robert I. BlumCEO, Pres & Director1.08M3.28M1964
Mr. Ching W. JawSr. VP & CFO645.6kN/A1963
Dr. Fady Ibraham Malik FACC, M.D., Ph.D.Exec. VP of R&D733.08k1M1964
Mr. Andrew M. CallosExec. VP & Chief Commercial Officer411.85kN/A1956
Dr. James A. Spudich Ph.D.Co-Founder & Member of Scientific Advisory BoardN/AN/A1942
Mr. Jeff LotzVP of Sales & OperationsN/AN/AN/A
Mr. Robert C. WongVP & Chief Accounting OfficerN/AN/A1968
Ms. Joanna SiegallAssociate Director of Corp. Communications & Investor RelationsN/AN/AN/A
Ms. Kari K. Loeser J.D.VP & Chief Compliance OfficerN/AN/AN/A
Mr. Scott R. JordanSr. VP of Global Marketing & Commercial StrategyN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Corporate Governance

Cytokinetics, Incorporated’s ISS Governance QualityScore as of July 31, 2022 is 6. The pillar scores are Audit: 9; Board: 4; Shareholder Rights: 7; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.